| __timestamp | ADMA Biologics, Inc. | Ionis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3742367 | 241751000 |
| Thursday, January 1, 2015 | 4311461 | 322292000 |
| Friday, January 1, 2016 | 6360761 | 344320000 |
| Sunday, January 1, 2017 | 29164321 | 374644000 |
| Monday, January 1, 2018 | 42194635 | 1820000 |
| Tuesday, January 1, 2019 | 39504238 | 4000000 |
| Wednesday, January 1, 2020 | 61291426 | 12000000 |
| Friday, January 1, 2021 | 79769341 | 11000000 |
| Saturday, January 1, 2022 | 118814535 | 14000000 |
| Sunday, January 1, 2023 | 169273000 | 9133000 |
| Monday, January 1, 2024 | 11215000 |
In pursuit of knowledge
In the ever-evolving biotech industry, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for Ionis Pharmaceuticals, Inc. and ADMA Biologics, Inc. over the past decade. From 2014 to 2023, Ionis Pharmaceuticals experienced a significant fluctuation in its cost of revenue, peaking in 2017 and then dramatically decreasing by 97% in 2018. In contrast, ADMA Biologics showed a steady increase, with a notable 352% rise from 2014 to 2023. This divergence highlights the strategic differences in managing production costs between the two companies. Ionis's sharp decline in costs post-2017 suggests a strategic pivot or operational efficiency improvements, while ADMA's consistent growth may indicate expansion or increased production capacity. Understanding these trends provides valuable insights into the financial strategies of leading biotech firms.
Comparing Cost of Revenue Efficiency: Eli Lilly and Company vs Ionis Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Johnson & Johnson and Ionis Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Merck & Co., Inc. vs Ionis Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Incyte Corporation vs Ionis Pharmaceuticals, Inc.
Viatris Inc. vs ADMA Biologics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Dr. Reddy's Laboratories Limited and Ionis Pharmaceuticals, Inc.
Cost of Revenue Trends: Sarepta Therapeutics, Inc. vs Ionis Pharmaceuticals, Inc.
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and ADMA Biologics, Inc.'s Expenses
Cost of Revenue Trends: Ionis Pharmaceuticals, Inc. vs CRISPR Therapeutics AG
Cost of Revenue Trends: Ionis Pharmaceuticals, Inc. vs PTC Therapeutics, Inc.
Ionis Pharmaceuticals, Inc. vs MorphoSys AG: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: ADMA Biologics, Inc. vs MiMedx Group, Inc.